New malaria vaccine trial aims to protect both adults and kids
NCT ID NCT06958198
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests a new malaria vaccine in healthy adults (18-35 years) and children (5-17 months) in Burkina Faso. The vaccine combines three parts of the malaria parasite to try to give stronger protection. The main goal is to check if it is safe and how well the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut de Recherche en Sciences de la Santé
RECRUITINGSiglé, Boulkiemdé Province, BP 7192 OUAGADOUGOU 03, BF, Burkina Faso
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.